Cognitive · Investigational
Nemifitide
No lawful US pathway
01 · Overview
Nemifitide (formerly INN 00835) is a synthetic pentapeptide analogue of melanocyte-inhibiting factor (MIF), not of alpha-MSH, developed as a fast-acting antidepressant (PMID 14985919). It was developed by Innapharma for the treatment of depression (PMID 14619408) and given by subcutaneous injection in clinical studies (PMID 16259645).
In rats bred as a genetic model of depression, it produced antidepressant-like effects after as little as five days of treatment (PMID 14985919).
02 · Research summary & key findings
In a 6-week randomized, placebo-controlled trial in 81 patients with major depressive disorder, the higher of two nemifitide doses was significantly superior to placebo at the time of peak effect, with tolerability comparable to placebo (PMID 16259645). In an open-label pilot study of 25 patients with chronic treatment-refractory depression, 11 responded on the main depression scale (PMID 18090505). No studies in stroke or brain injury were found, and nemifitide has not been approved.
03 · Regulatory status
Nemifitide is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
No lawful pathway today
Nemifitide is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for cognitive support?
Nemifitide is an investigational compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on cognitive support, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Intravenous
References
- [1]Nemifitide. Innapharma Curr Opin Investig Drugs, 2003. PMID 14619408
- [2]Antidepressant-like effects of a novel pentapeptide, nemifitide, in an animal model of depression Psychopharmacology (Berl), 2004. PMID 14985919
- [3]Efficacy and safety of 30 mg/d and 45 mg/d nemifitide compared to placebo in major depressive disorder Int J Neuropsychopharmacol, 2006. PMID 16259645
- [4]Clinical effect of nemifitide, a novel pentapeptide antidepressant, in the treatment of severely depressed refractory patients Int Clin Psychopharmacol, 2008. PMID 18090505
Primary literature
- PubMed: "Nemifitide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Nemifitide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Nemifitide"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Cognitive
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.